Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.
-
Lu par :
-
De :
À propos de ce contenu audio
In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header